A detailed history of New Edge Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, New Edge Advisors, LLC holds 160,041 shares of BMY stock, worth $9.24 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
160,041
Previous 274,740 41.75%
Holding current value
$9.24 Million
Previous $11.4 Million 27.41%
% of portfolio
0.06%
Previous 0.08%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$39.66 - $51.75 $4.55 Million - $5.94 Million
-114,699 Reduced 41.75%
160,041 $8.28 Million
Q2 2024

Aug 15, 2024

BUY
$40.25 - $52.99 $6 Million - $7.89 Million
148,973 Added 118.45%
274,740 $11.4 Million
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $100,805 - $114,294
2,101 Added 1.7%
125,767 $6.82 Million
Q4 2023

Feb 13, 2024

SELL
$48.48 - $57.85 $3.46 Million - $4.13 Million
-71,387 Reduced 36.6%
123,666 $6.35 Million
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $1.98 Million - $2.22 Million
-34,229 Reduced 14.93%
195,053 $11.3 Million
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $26.4 Million - $29.3 Million
-413,924 Reduced 64.35%
229,282 $14.7 Million
Q1 2023

May 12, 2023

BUY
$65.71 - $74.53 $2.43 Million - $2.76 Million
37,045 Added 6.11%
643,206 $44.6 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $4.55 Million - $5.39 Million
66,507 Added 12.32%
606,161 $43.6 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $48,049 - $28.4 Million
369,610 Added 217.36%
539,654 $38.4 Million
Q2 2022

Aug 09, 2022

BUY
$72.62 - $79.98 $341,894 - $376,545
4,708 Added 2.85%
170,044 $13.1 Million
Q1 2022

May 13, 2022

BUY
$61.48 - $73.72 $3.53 Million - $4.23 Million
57,444 Added 53.24%
165,336 $12.1 Million
Q4 2021

Feb 17, 2022

BUY
$53.63 - $62.52 $3 Million - $3.5 Million
55,948 Added 107.71%
107,892 $6.73 Million
Q3 2021

Oct 29, 2021

SELL
$59.17 - $69.31 $62,246 - $72,914
-1,052 Reduced 1.99%
51,944 $3.07 Million
Q2 2021

Jul 22, 2021

BUY
$61.91 - $67.42 $67,853 - $73,892
1,096 Added 2.11%
52,996 $3.54 Million
Q1 2021

Apr 26, 2021

BUY
$59.34 - $66.74 $195,406 - $219,774
3,293 Added 6.77%
51,900 $3.28 Million
Q4 2020

Jan 27, 2021

SELL
$57.74 - $65.43 $2.35 Million - $2.67 Million
-40,743 Reduced 45.6%
48,607 $3.02 Million
Q3 2020

Nov 03, 2020

SELL
$57.43 - $63.64 $1.08 Million - $1.2 Million
-18,875 Reduced 17.44%
89,350 $5.39 Million
Q2 2020

Jul 29, 2020

BUY
$54.82 - $64.09 $1.02 Million - $1.19 Million
18,582 Added 20.73%
108,225 $6.36 Million
Q1 2020

May 04, 2020

BUY
$46.4 - $67.43 $612,851 - $890,615
13,208 Added 17.28%
89,643 $5 Million
Q4 2019

Jan 31, 2020

BUY
$49.21 - $64.19 $2.07 Million - $2.71 Million
42,151 Added 122.95%
76,435 $4.91 Million
Q3 2019

Nov 06, 2019

BUY
$42.77 - $50.71 $993,119 - $1.18 Million
23,220 Added 209.87%
34,284 $1.79 Million
Q2 2019

Aug 05, 2019

BUY
$44.62 - $49.34 $847 - $937
19 Added 0.17%
11,064 $502,000
Q1 2019

May 09, 2019

BUY
$45.12 - $53.8 $39,886 - $47,559
884 Added 8.7%
11,045 $49,000
Q4 2018

Jan 29, 2019

SELL
$48.76 - $63.23 $9,264 - $12,013
-190 Reduced 1.84%
10,161 $528,000
Q3 2018

Oct 29, 2018

BUY
$55.19 - $62.25 $571,271 - $644,349
10,351 New
10,351 $643,000
Q2 2018

Jul 19, 2018

SELL
$50.53 - $62.98 $265,383 - $330,770
-5,252 Closed
0 $0
Q1 2018

May 11, 2018

BUY
$59.92 - $68.98 $24,866 - $28,626
415 Added 8.58%
5,252 $326,000
Q4 2017

Feb 08, 2018

BUY
$59.94 - $65.35 $26,733 - $29,146
446 Added 10.16%
4,837 $299,000
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $497 - $573
9 Added 0.21%
4,391 $282,000
Q2 2017

Aug 16, 2017

BUY
N/A
4,382
4,382 $0

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.